Home > Monoclonal Antibody Based Products (Table of Contents)

Monoclonal Antibody Based Products

Global Industry Analysts
October 1, 2008
527 Pages - SKU: GJOB2073343

Abstract Table of Contents Related Reports

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Quantitative Techniques & Analytics; Cancer
II. EXECUTIVE SUMMERY: 1. Industry Overview; World MAb-Based Products Market: A Profile; Therapeutic mAb Market - Principal Driving Force; Genomics Research Leads Way to New Monoclonal Antibodies; Product Segment Perspective; Table 1: Major Acquisitions of Antibody-Focused Companies (2005-2007); Table 3: Leading Drugs in the Global Therapeutic Monoclonal Antibodies Market (2006): Percentage Breakdown of Dollar Sales for Remicade, Rituxan, Herceptin, Avastin, Humira, Erbitux, Synagis, Xolair and Others (includes corresponding Graph/Chart); Table 6: Leading Products in the Global Oncology Monoclonal Antibodies Market (2008E): Percentage Share Breakdown of Sales for Avastin, Herceptin, Rituxan, Erbitux, and Others (includes corresponding Graph/Chart); Drug Developers Trying to Break the Shackles; A Revolution Not too Far; Evolution of Monoclonal Antibodies - A Historical Journey; Trends and Issues; Partnerships and Collaborations Spark Increase in Profit Margins; Select Clinical Trials for Monoclonal Antibodies; Major Monoclonal Antibodies in Phase III Trials Across the World; Opportunities in Technology Development; FCA- A Major Cause for Discomfort in Mice; Immune System: Natural Defenders; Polyclonal and Monoclonal Antibodies; Factors Impacting Production of MAbs; Humanized Antibodies/ CDR Grafted Antibodies; Chimeric Antibodies: Show Lesser Antigenicity; Advantages of MAbs; 4. Diagnostic Applications of Monoclonal Antibodies; Monoclonal Antibody Based Diagnostics; The Pros and Cons of MAb-Based Immunoconjugates; Cancer; 5. Monoclonal Antibody-Based Therapeutics; Evolution of Therapeutic Antibody Products; Current Scenario in Monoclonal Antibody Therapeutics Market; Cancer Therapeutics; Monoclonal Antibody Cancer Therapies Under Development; Cancer: A Serious Issue and Plaguing Illness Worldwide; Monoclonal Antibodies Against NHL; Immunologic Effector Functions; 6. Other Therapeutic Monoclonal Antibodies; Therapeutic Monoclonal Antibody Drugs and Applications; Asthma: A Chronic Affliction; Intervention Better Than Prevention; Crohn’s Disease; Syngeneic Transplants; Infectious Diseases; A Retrospect; Global Statistics; Treatment Options; 7. Regulation Impacting The Industry; Regulations in the U.S; Orphan Drug Status; 8. Research and Development Activities; Rituxan and Herceptin from Genentech; GenMAb Develops Fully Human Antibodies; 9. Product Launches and Developments; Amgen Introduces Vectibix; Dr. Reddy’s Introduces Reditux™; Genentech Introduces Xolair; 10. Recent Industry Activity; EUSA Pharma to Take Over Cytogen; Access Pharmaceuticals Acquires Somanta Pharmaceuticals; Genmab Enters into Antibody Research Collaboration with Pepscan; Eusa Sells Antibody Research Business; HGS Reacquires Rights for TRAIL Receptor Antibodies; Dyax and Sanofi-Aventis Sign Agreements; CSL Limited Inks a Collaboration Agreement with Celltrion; Astellas US Holding Takes Over Agensys; Genentech Acquires Tanox; GTC and LFB Commence CD20 Monoclonal Antibody Development; BioArctic and Eisai Announce Licensing Agreement; CMC Biopharmaceuticals Inks Agreement with Biotest; Abeome Enters into Distribution Agreement with Millipore; Favrille Acquires Diversa’s Anti-CD20 Monoclonal Antibodies; Merck Acquires Abmaxis; Xencor Extends R&D Collaboration with Roche; Akorn and Serum Institute Enter into Development and Distribution Agreement; Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal Antibody Drug; Candidates; Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for Cancer; Treatment; Therapeutics; Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business; XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal; Antibodies; UCB Collaborates with Millenium; H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics; Research; ImmunoGen Signs Licensing Agreement with Biogen; MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials; CAT Signs Licensing Agreement with Micromet; InNexus and Corixa Enter into Agreement; Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody; Research; Epicyte and Dow Chemical Enter into Agreement; PDL Signs Agreement with InterMune; MedImmune and Alkermes Enter into Agreement; Amgen, Inc. (US); Biogen Idec Inc (US); CMC ICOS Biologics, Inc; Eli Lilly and Company (US); Human Genome Sciences, Inc. (US); Johnson & Johnson (US); Ortho Biotech Products, L.P. (US); PDL BioPharma (US); Strategic Diagnostics Inc (US); 13. Global Market Perspective; Table 10: World Recent Past, Current & Future Market Analysis for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 11: World Long-term Projections for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 12: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 13: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 14: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 15: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 16: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment - Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 18: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Segments - Percentage Breakdown of Dollar Sales for Cancer and Other Therapeutics Markets for Years 2003, 2008 & 2012; Table 19: World Recent Past, Current & Future Market Analysis for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 20: World Long-term Projections for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 21: World 10-Year Perspective for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 22: World Recent Past, Current & Future Market Analysis for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 23: World Long-term Projections for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 24: World 10-Year Perspective for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 25: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 26: World Long-term Projections for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 27: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
III. MARKET: 1. The Untied States; A. Market Analysis; Therapeutic Monoclonal Antibodies Market - An Overview; Leading Products; Table 29: Leading Players in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Share Breakdown of Revenues for Genentech Inc, Centocor, MedImmune, Bristol Meyer's Squibb, Amgen, Hoffman-La Roche, and Others (includes corresponding Graph/Chart); BD Biosciences; CMC ICOS Biologics, Inc; Eli Lilly and Company; Immunomedics; Johnson & Johnson; MedImmune, Inc; PDL BioPharma; Wyeth Pharmaceuticals; Strategic Developments; B. Market Analytics; Table 32: US 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 2. Canada; A. Market Analysis; Strategic Developments; B. Market Analytics; Table 35: Canadian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 3. Japan; A. Market Analysis; B. Market Analytics; Table 38: Japanese 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4. Europe; A. Market Analysis; Need to Reduce Complexities, Time & Cost of mAb Development; Emerging Radioimmunotherapy Products; B. Market Analytics; Table 41: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart); Table 43: European 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region -Percentage Breakdown of Dollar Sales for France, Germany, Italy, The UK, and Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart); Table 44: European 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4a. France; A. Market Analysis; B. Market Analytics; Table 47: French 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4b. Germany; A. Market Analysis; Strategic Developments; B. Market Analytics; Table 50: German 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4c. Italy; Market Analysis; Table 52: Italian Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 53: Italian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4d. The United Kingdom; A. Market Analysis; Product Launches; B. Market Analytics; Table 56: UK 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 4e. Rest of Europe; A. Market Analysis; Strategic Developments; B. Market Analytics; Table 58: Rest of Europe Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart); Table 59: Rest of Europe 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart); 5. Rest of World; A. Market Analysis; B. Market Analytics; Table 62: Rest of World 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE: Total Companies Profiled: 123 (including Divisions/Subsidiaries - 144); Region/Country Players; The United States 89; Canada 6; Japan 6; Europe33; France5; Germany 7; The United Kingdom6; Italy 1; Spain 1; Rest of Europe 13; Asia-Pacific (Excluding Japan) 9; Middle-East1

Research assistance

We can help you find what you need. Call us or write us:

US: 800.298.5699

Int'l: +1.240.747.3093

Need help in your search?

Related Markets

Antibody Technologies Reports

Share this report

Email a colleague

Other tasks

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!